Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ANP32A
REST API REST API
Homo sapiens
ANP32A is differentially expressed in 356 experiments: 164 organism parts: cerebellum, thymus, ... (162 more);, 260 disease states: normal, acute lymphoblastic leukemia, ... (258 more);, 120 cell types 513 cell lines 57 compound treatments and 84 other conditions.
Synonyms LANP, PHAPI, I1PP2A, PP32, C15orf1, mapmodulin, MAPM
Orthologs D3ZEQ3_RAT (Rattus norvegicus)   ENSCING00000012732 (Ciona intestinalis)   anp32a (Danio rerio)   AN32A_BOVIN (Bos taurus)   Anp32a (Mus musculus)   Anp32a (Rattus norvegicus)   D3ZLL4_RAT (Rattus norvegicus)   ENSGALG00000008054 (Gallus gallus)   Mapmodulin (Drosophila melanogaster)   anp32a (Xenopus laevis)   AN32A_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term endoplasmic reticulum, protein binding, regulation of transcription, DNA-dependent, cytoplasm, RNA metabolic process, nucleus, perinuclear region of cytoplasm, nucleoplasm, nucleocytoplasmic transport, mRNA metabolic process, intracellular signal transduction
InterPro Term U2A'_phosphoprotein32A_C, Leu-rich_rpt
UniProt Accession Q08AJ6, P39687, Q6PKH8, F2Z3H3
Search EB-eye ENSG00000140350
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (46 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
T84
2
E-GEOD-1474, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
HCC38
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
SW480
2
E-GEOD-18005, E-MEXP-1014
507 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (53 experiments)

Factor Value U/D Experiments
macrophage
3
E-GEOD-22373, E-GEOD-3982, E-GEOD-5099
fibroblast
3
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18147, E-GEOD-18265
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
114 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (70 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
3
E-MTAB-62, E-GEOD-96, E-GEOD-5550
glioblastoma
3
E-MTAB-37, E-GEOD-4290, E-GEOD-4412
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-MTAB-62
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
acute promyelocytic leukemia
2
E-GEOD-96, E-MTAB-62
254 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-697, ... (36 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-3284, E-GEOD-4006
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
CNOT7+CNOT8
1
E-MEXP-2218
17beta-estradiol
5
1
E-GEOD-4006
-
1
1
E-MEXP-2645
5-fluorouridine
1
E-GEOD-995
51 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-MEXP-2280, E-TABM-147, E-GEOD-21138, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-2466, E-TABM-868, E-TABM-601, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-10315, E-TABM-440, E-TABM-263, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-2069, ... (42 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321, E-MEXP-2177

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22229, E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, ... (10 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, ... (6 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.493 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM